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Abstract
INTRODUCTION: P21-activated kinase 4 (PAK), a subfamily of serine/threonine kinases originally known as a reg-
ulator of cytoskeletal dynamics and cell motility, has recently been revealed to play a key role in oncogenic signal-
ing pathways. We studied the frequency and clinical features of PAK4-overexpressed metastatic gastric cancer.
PATIENTS AND METHODS: PAK4 overexpression was screened by Western blot in 18 human gastric cancer cell
lines. Immunohistochemical staining of PAK4 protein was performed in tumor specimens of 49 metastatic gastric
cancer patients who received palliative capecitabine/cisplatin as first-line treatment. RESULTS: PAK4 protein over-
expression was detected strongly in five gastric cell lines (AGS, MGK-28, MKN-74, SNU-216, SNU-601) and weakly
in four cell lines (KATOIII, MKN-1, SNU-620, and SNU-719). PAK4 knockdown by small interfering RNA induced
apoptosis in PAK4-overexpressed AGS gastric cancer cells. Immunohistochemical staining revealed PAK4 over-
expressions in 4 (8.1%) of 49 metastatic gastric cancer specimens. None of the four patients with PAK4(+) re-
sponded to capecitabine/cisplatin chemotherapy, and PAK4(+) gastric cancer patients had a trend of poorer
survival compared with PAK(−) (P = .876). CONCLUSIONS: We demonstrated PAK4 overexpression in a subset
of gastric cancer patients, implicating a role in gastric cancer tumorigenesis. Its prognostic significance and effi-
cacy as a drug target should be further studied.
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Introduction
Gastric cancer is the most common cancer type and the major cause
of cancer death in Korea [1]. Although most of the newly diagnosed
gastric cancer patients undergo curative resection, more than 50% of
the patients with advanced gastric cancer develop recurrence after sur-
gery. Thus, novel treatment strategies should be actively sought in
advanced gastric cancer. P21-activated kinases (PAKs), conserved
serine/threonine kinases that have recently been found to be key reg-
ulators of cancer cell signaling networks, play fundamental roles in a
wide spectrum of cancer cellular mechanisms, including cancer cell
motility, survival, apoptosis, and metastasis [2–5]. PAKs were firstly
identified as the effectors for the small GTPases Cdc42 and Rac [6]
and associated with cytoskeletal dynamics and actin depolymerization
[6,7]. Six mammalian Paks have been identified and classified into
groups 1 (PAKs1-3) and 2 (PAKs4-6) [8]. Previous studies have con-
firmed the overexpression of PAK4 in an array of cancer cell lines [2].
Recently, Pak4 overexpression and activation were associated with
cancer metastasis, reduced patient survival, advanced stage, and increased
resistance to chemotherapy in ovarian cancer [9]. PAK4 is thought to
promote cancer cell progression through the regulation of c-Src,
MEK-1/ERL1/2, MMP2, and c-Src/EGFR [9]. There is an increasing
body of evidence that Pak4 may be a novel therapeutic target in many
cancer types including gastric cancer [10]. The importance of PAK4
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has been rehighlighted with the development of PAK4 kinase inhibitors
as anticancer agents [6,7,11]. We undertook this study to survey the
proportion of metastatic gastric cancer patients harboring Pak4 over-
expression and to correlate the PAK4 positivity with treatment out-
come to first-line capecitabine/cisplatin chemotherapy.
Patients and Methods
Cell Culture and Reagents
Eighteen human gastric cancer cell lines (AGS of moderately to
poorly differentiated primary gastric adenocarcinoma; MKN-45 from
poorly differentiated adenocarcinoma; MKN-28 and MKN-74 from
gastric tubular adenocarcinoma; MKN-1 from gastric adenosquamous
cell carcinoma; SNU-719 from moderately differentiated adeno-
carcinoma; SNU-216 and NCI-N87 from metastatic gastric adenocar-
cinoma; SNU-1, SNU-484, and SNU-520 from poorly differentiated
primary gastric adenocarcinoma; KATOIII, SNU-601, and SNU-668
from metastatic signet ring cell carcinoma; and SNU-16, SNU-5,
SNU-620, and SNU-638 from ascites of poorly differentiated adeno-
carcinoma) were purchased from Korea Cell Line Bank (Seoul, South
Korea). All of the cell lines were grown in RPMI-1640 medium (PAA
Laboratories GmbH, Pasching, Austria) supplemented with 10% heat-
inactivated fetal bovine serum and antibiotic/antimycotic. Cells were
incubated at 37°C in 5% CO2, and the medium was changed twice
a week. After confluence, cells were subdivided into new flasks until
the end of the experiment.
Small Interfering RNA Treatment of AGS Cells
PAK4 targeting small interfering RNA (siRNA) and control siRNA
were obtained from Dharmacon (Lafayette, CO). AGS cells were
transfected with siRNA with Effectine transfection reagent as per the
manufacturer’s protocol (Qiagen, Hilden, Germany).
Western Blot Analysis
Total cell extracts were obtained using lysis buffer containing 20 mM
HEPES (pH 7.4), 150 mMNaCl, 1 mMMgCl2, 1 mM EDTA, 2 mM
EGTA, 10% glycerol, 1% Triton X-100, 1 μg/ml leupeptin, and 1 μg/ml
aprotinin. Equal amounts (30 μg) of cell lysates were dissolved in 8% or
12% Tris-glycine gels with TrisGly running buffer (Invitrogen, Novex,
Carlsbad, CA), transferred onto nitrocellulose membrane, and incubated
with following specific antibodies: polyclonal rabbit PAK4 antibody
(ab62509; Abcam plc, Cambridge, United Kingdom), cleaved caspase-3
antibody (9664; Cell Signaling Technology, Boston, MA), cleaved
caspase-9 antibody (9501; Cell Signaling Technology), cleaved PARP
antibody (9541; Cell Signaling Technology), and rabbit polyclonal
tubulin (sc9104; Santa Cruz Biotechnology, Santa Cruz, CA). Immune
complexes were visualized by enhanced chemiluminescence (Novex
ECL, Invitrogen).
Patients
From February 2009 to July 2010, 49 metastatic gastric cancer
patients who received palliative capecitabine/cisplatin chemotherapy
had tumor specimens available for immunohistochemical staining.
Figure 1. (A) Results of PAK4 expression level test using by Western blot. (B) Results of PAK4 knockdown by siRNA treatment in PAK4-
overexpressed AGS cancer cell lines.
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Formalin-fixed paraffin sections were stained with polyclonal rabbit
anti-Pak4 antibody (ab62509; Abcam plc) with 1:500 dilution. (All
tumor slides were reviewed by one pathologist who is an expert in
gastrointestinal pathology [K.-M.K.].) All clinical and pathologic
variables were collected. Treatment response to capecitabine/cisplatin
chemotherapy was evaluated by RECIST 1.0 criteria [12]. The pro-
tocol has been approved by the institutional review board at Samsung
Medical Center.
Statistical Analyses
Overall survival was measured from the first date of palliative che-
motherapy to the date of death. Overall survival was calculated using
the Kaplan-Meier method. Correlation analyses of the expression of
PAK4 with clinical and pathologic variables were performed using
the two-sided χ2 test or Fisher exact test. Difference in overall survival
according to expressions of PAK4 was compared using log-rank test.
P < .05 was considered statistically significant.
Results
PAK4 overexpression was screened in 18 gastric cancer cell lines
in vitro by immunoblot analysis. As shown in Figure 1A, PAK4 pro-
tein overexpression was strongly detected in five cell lines (AGS,
MKN-28, MKN-74, SNU-216, and SNU-601) and weakly in four
cell lines (KATOIII, MKN-1, SNU-620, and SNU-719). AGS
gastric cancer cells with high levels of PAK4 protein expression were
treated with PAK4 targeting siRNA (Figure 1B). siPAK4 treatment
induced apoptosis in AGS cells as confirmed by caspase 3, caspase 9,
and PARP cleavages.
Next, we surveyed the PAK4 overexpression in 49 tumor specimens
patients with from metastatic, unresectable gastric cancer who received
first-line capecitabine/cisplatin chemotherapy. Twenty-one patients
(42.9%) had poorly differentiated adenocarcinoma and 16 patients
(32.7%) had signet ring cell carcinoma. At the time of first-line
palliative chemotherapy, the most common sites of metastases were
as follows in the order of frequency: 27 (55.1%) peritoneal seeding,
15 (30.6%) distant lymph node metastases, 5 (10.2%) ovarian metas-
tases, and 5 (10.2%) liver metastases (Table 1). A representative photo-
micrograph of immunohistochemical staining for PAK4 is provided
in Figure 2. In positive cases, PAK4 was stained deep brown in the cy-
toplasm of tumor cells. All four cases positively stained for PAK4 were
poorly differentiated tubular adenocarcinomas. None of differentiated-
type adenocarcinomas or signet ring cell carcinomas were positive for
PAK4. Correlative analyses between PAK4 and clinical parameters dem-
onstrated no significant relationship with age, Lauren type, lymphovascular
Table 1. Patients’ Characteristics.
Characteristics
Age (years)
Median, range 53, 28-76
Sex, n (%)
Male 35 (71.4)
Female 14 (28.6)
Timing of distant metastasis, n (%)
Synchronous 42 (85.7)
Metachronous 5 (10.2)
Unresectable 2 (4.1)
Type of gastrectomy, n (%)
Subtotal 4 (8.1)
Total 12 (24.4)
None 31 (63.3)
Palliative bypass surgery 2 (4.0)
Location of tumor, n (%)
Distal 1/3 14 (28.6)
Middle 1/3 16 (32.7)
Proximal 1/3 11 (22.4)
Diffuse 8 (16.3)
Histologic diagnosis, n (%)
Well differentiated adenocarcinoma 0 (0)
Moderately differentiated adenocarcinoma 10 (20.4)
Poorly differentiated adenocarcinoma 21 (42.9)
Signet ring cell carcinoma 16 (32.7)
Others 2 (4.0)
Extent of disease at the time of diagnosis of distant metastasis, n (%)
Confined to peritoneum (including peritoneal seeding) 27 (55.1)
Confined to intra-abdominal solid organ 11 (22.4)
Extra-abdominal metastasis 9 (18.4)
Locally advanced, unresectable 2 (4.0)
Metastatic site, n (%)
Peritoneum or omentum 27 (55.1)
Lymph node 15 (30.6)
Ovary 5 (10.2)
Liver 5 (10.2)
Ascites 4 (8.1)
Lung 3 (6.1)
Bone 3 (6.1)
Figure 2. PAK4 overexpression in gastric cancer by immunohistochemical staining.
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invasion, histologic diagnosis, and tumor extent (Table 2). Of note,
none of the four PAK4(+) gastric cancer patients demonstrated re-
sponse to capecitabine/cisplatin chemotherapy. One patient initially
responded to two cycles of capecitabine/cisplatin but did not maintain
the response for more than 4 weeks and developed disseminated dis-
ease. The remaining three patients did not respond to chemotherapy.
Hence, although statistical significance could not be reached because of
the small number of gastric carcinomas with PAK4(+), the response rate
to capecitabine/cisplatin was low (0%) in PAK4(+) patients when com-
pared with PAK4(−) (24.4%) patients. In line with this, patients with
PAK4(+) gastric cancer had a tendency toward poorer survival when
compared with PAK(−) gastric cancer patients (P = .876; Figure 3).
Discussion
The survival outcome of metastatic gastric cancer patients despite
palliative chemotherapy is still unsatisfactory. On the basis of our re-
cent retrospective analysis on 1455 unresectable, metastatic gastric
cancer patients who were treated palliative chemotherapy from
1994 to 2005, the median survival time was only 8.6 months
(95% confidence interval [CI], 8.1-9.1 months) [13]. Recently,
the first molecular target with significant survival benefit was identi-
fied in gastric cancer. In TOGA trial, median survival time was 13.8
months (95% CI, 12-16 months) in HER2(+) patients assigned to
trastuzumab plus 5-fluorouracil/cisplatin or capecitabine/cisplatin
when compared with 11.1 months (95% CI, 10-13 months; P =
.0046) [14]. Through this trial, the potential survival benefit from
molecularly targeted agents in specific segments of gastric patient
population has been strongly suggested, which warrants further inves-
tigation for molecular targets. Recently, PAK4 has been highlighted as
a potential novel target for solid tumors [7,10,15]. PAK4 inhibitors
effectively inhibited PAK4-dependent pathways leading to tumor
shrinkage in multiple human tumor xenografts including colon, breast,
lung, and melanoma [7]. Nevertheless, PAK4 inhibitors or PAK4 over-
expression have not been extensively surveyed in gastric cancer yet. The
expression of PAK4 has been reported in one small study, which
reported a significant and positive correlation between PAK4 expression
and lymph node metastasis [16].
Callow et al. [2] analyzed the roles of PAK4 and PAK6 have been
tested in a panel of cell lines derived from leukemias, melanomas,
breast cancer, colon cancer, lung cancer, liver cancer, ovarian cancer,
and renal cancer. They found that the PAK4 gene localizes at a region
of chromosome 19, which is commonly amplified in a number of
Table 2. Comparison of Clinical Features According to PAK4 Expression.
No. cases (N = 49) PAK4 Expression
Positive (n = 4) Negative (n = 45) P
Age (years)
≤60 35 (70.8%) 3 (75.0%) 32 (70.5%) N-C
>60 14 (29.2%) 1 (25.0%) 13 (29.5%)
Lauren type
Intestinal 7 (14.3%) 0 (0%) 7 (15.6%) N-C
Diffuse 7 (14.3%) 1 (25.0%) 6 (13.3%)
Mixed 2 (4.1%) 0 (0%) 2 (4.4%)
Unknown 33 (67.3%) 3 (75.0%) 30 (66.7%)
Lymphovascular invasion
Presence 14 (28.6%) 1 (25.0%) 13 (28.9%) N-C
Absence 1 (2.0%) 0 (0%) 1 (2.2%)
Unknown 34 (69.4%) 3 (75.0%) 31 (68.9%)
Histologic diagnosis
Adenocarcinoma 33 (67.3%) 3 (75.0%) 30 (66.7%) N-C
Signet ring cell carcinoma 16 (32.7%) 1 (25.0%) 15 (33.3%)
Best response to capecitabine/cisplatin chemotherapy
CR/PR 12 (24.5%) 0 (0.0%) 11 (24.4%) N-C
SD 28 (57.1%) 3 (75.0%) 25 (55.6%)
PD 7 (14.3%) 1 (25.0%) 7 (15.6%)
Not evaluated 2 (4.1%) 0 (0%) 2 (4.4%)
Metastatic sites
Confined to intraperitoneuthem (peritoneum, omentum,
ascites, ovary, intra-abdominal lymph node)
36 (73.5%) 3 (75.0%) 33 (73.3%) N-C
Extraperitoneal organs (lung, liver, bone) 13 (26.5%) 1 (25.0%) 12 (26.7%)
CR indicates complete remission; N-C, not contributable; PD, progressive disease; PR, partial remission; SD, stable disease.
Figure 3. Comparison of overall survival according to PAK4 over-
expression status in 49 gastric cancer patients.
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human pancreatic cancer, colon cancer, and ovarian cancers. The
PAK4 messenger RNA and gene amplification were not tested in
our series; however, there are several reports that support a strong
correlation between amplification and protein expression in multiple
cancer types [9,10].
In line with our study, the association between chemoresistance
and PAK4 overexpression has been suggested in ovarian cancer. They
surveyed PAK4 overexpression in relation to response to paclitaxel/
platinum in 70 ovarian cancer patients and found that patients with
high scores of total PAK protein were significantly correlated with
poor response to first-line chemotherapy [9]. Although any conclu-
sion is limited from small sample size, none of the PAK4(+) patients
responded to first-line capecitabine/cisplatin chemotherapy. The
prognostic significance of PAK4 needs to be validated in a larger
patient cohort. Of note, our preclinical in vitro test demonstrated
that PAK4 knockdown by siRNA-induced apoptosis in PAK4(+)
gastric cancer cell line. Whether PAK4 overexpression will represent
another subgroup of gastric cancer patients such as HER2(+) with
effective druggable target should be evaluated in future clinical trials.
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